Scientists make precise gene edits to mitochondrial DNA for first time
By Heidi Ledford,
Nature
| 07. 08. 2020
A peculiar bacterial enzyme has allowed researchers to achieve what even the popular CRISPR–Cas9 genome-editing system couldn’t manage: targeted changes to the genomes of mitochondria, cells’ crucial energy-producing structures.
The technique — which builds on a super-precise version of gene editing called base editing — could allow researchers to develop new ways to study, and perhaps even treat, diseases caused by mutations in the mitochondrial genome. Such disorders are most often passed down maternally, and impair the cell’s ability to generate energy. Although there are only a small number of genes in the mitochondrial genome compared with the nuclear genome, these mutations can particularly harm the nervous system and muscles, including the heart, and can be fatal to people who inherit them.
But it has been difficult to study such disorders, because scientists lacked a way to make animal models with the same changes to the mitochondrial genome. The latest technique marks the first time that researchers have made such targeted changes, and could allow researchers to do this. “It’s a very exciting development,” says Carlos Moraes, a mitochondrial geneticist...
Related Articles
By Tristan Manalac, BioSpace | 04.02.2024
Verve Therapeutics has suspended enrollment in the Phase Ib Heart-1 study evaluating its lead gene editing program VERVE-101 following a serious adverse event, the company announced Tuesday.
A patient, who received a 0.45-mg/kg dose of VERVE-101, developed a grade 3...
By Timnit Gebru and Émile P. Torres, First Monday | 04.14.2024
The stated goal of many organizations in the field of artificial intelligence (AI) is to develop artificial general intelligence (AGI), an imagined system with more intelligence than anything we have ever seen. Without seriously questioning whether such a system can...
By Harold Brubaker, The Philadelphia Inquirer | 04.04.2024
Acompany started by University of Pennsylvania scientist Jim Wilson has received FDA approval to test a form of gene editing in infants for the first time in the United States, the company said Thursday.
The Plymouth Meeting company, iECURE, is...
By Judith Levine, The Intercept | 04.04.2024
WHEN THE ALABAMA Supreme Court ruled that fertilized embryos were “extrauterine children,” it did more than imperil the future of in vitro fertilization in Alabama and, potentially, the U.S. The ruling, on the claimed “wrongful death” of frozen embryos...